PsiOxus Therapeutics was formed in 2010 through the combination of Myotec Therapeutics Ltd and Hybrid Biosystems Ltd.
Myotec
Myotec was formed in 2006 as an Imperial College spin out company based upon the world leading research of Professor Stefan Anker and Professor Andrew Coats into the underlying mechanisms of cachexia across a wide range of chronic disease states. Myotec identified and developed the lead program, MT-102, to the point of phase II clinical development. MT-102 has a unique combination of pharmacological effects to produce a Anabolic Catabolic transforming Agent (ACTA) with an excellent pre-clinical efficacy profile, as demonstrated in animal models of cachexia and sarcopenia. MT-102 has been dosed to 132 patients in two clinical studies and has a very good human safety profile. MT-102 and our follow-on programs are being developed in close collaboration with Professor Anker’s specialist cachexia research group at the Charité Medical School in Berlin.
Hybrid
Hybrid based upon the ground-breaking research of Professor Len Seymour and Dr Kerry Fisher. Hybrid's early research was into the use of viruses as a unique form of therapeutics. ColoAd1 was developed in collaboration with Berlex (now Bayer Schering) as a unique chimeric oncolytic virus. Hybrid's scientists also developed the stealthed vaccine vector system called PolySTAR,which is a polymer coated recombinant viral vector and the potent adjuvant and immunotherapeutic system called PolyMAP.